- Home
- AYRO vs ENVB Comparison
AYRO vs ENVB Comparison
Compare AYRO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- ENVB
- Stock Information
- Founded
- AYRO 2017
- ENVB 1994
- Country
- AYRO United States
- ENVB United States
- Employees
- AYRO N/A
- ENVB N/A
- Industry
- AYRO Telecommunications Equipment
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- ENVB Health Care
- Exchange
- AYRO Nasdaq
- ENVB Nasdaq
- Market Cap
- AYRO 4.8M
- ENVB 4.1M
- IPO Year
- AYRO N/A
- ENVB N/A
- Fundamental
- Price
- AYRO $0.70
- ENVB $0.35
- Analyst Decision
- AYRO
- ENVB Strong Buy
- Analyst Count
- AYRO 0
- ENVB 1
- Target Price
- AYRO N/A
- ENVB $10.00
- AVG Volume (30 Days)
- AYRO 193.8K
- ENVB 1.0M
- Earning Date
- AYRO 11-14-2024
- ENVB 11-14-2024
- Dividend Yield
- AYRO N/A
- ENVB N/A
- EPS Growth
- AYRO N/A
- ENVB N/A
- EPS
- AYRO N/A
- ENVB N/A
- Revenue
- AYRO $221,671.00
- ENVB N/A
- Revenue This Year
- AYRO $2,424.87
- ENVB N/A
- Revenue Next Year
- AYRO N/A
- ENVB N/A
- P/E Ratio
- AYRO N/A
- ENVB N/A
- Revenue Growth
- AYRO N/A
- ENVB N/A
- 52 Week Low
- AYRO $0.64
- ENVB $0.30
- 52 Week High
- AYRO $1.86
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- AYRO 47.30
- ENVB 46.61
- Support Level
- AYRO $0.64
- ENVB $0.35
- Resistance Level
- AYRO $0.72
- ENVB $0.39
- Average True Range (ATR)
- AYRO 0.06
- ENVB 0.05
- MACD
- AYRO -0.00
- ENVB -0.00
- Stochastic Oscillator
- AYRO 44.71
- ENVB 19.56
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.